Schwenk H U, Schneider U
Klin Wochenschr. 1979 May 3;57(9):467-73. doi: 10.1007/BF01477500.
B-Cell-allo-antigen was demonstrated on lymphoblasts of children with acute lymphoblastic leukemia and on 14 permanent growing lymphoblastoid cell-lines. Pooled sera of 4 selected multiparas and a rabbit antiserum were used as specific antisera. Antigen was more effectively detected with heterologous antibodies than with human antisera. Primary lymphoblasts were characterized by B-cell-allo-antigen and lack of membrane immunoglobulins and Fc-receptors on the same cell. The quality of remission, i.e. the early diagnosis of relapse was better surveyed by immunological characterization than by cytological assessment. The bone marrow was examined in 8 patients with initial leukemia, in 13 patients with partial remission and in 30 patients in complete hematological remission. A striking discrepancy between immunological and cytological examination was observed in the bone marrow 4 weeks after inital anti-leukemic chemotherapy. At that time an increased number of blast-typed cells could still be counted in the immunological evaluation, although the cytological evaluation revealed already a complete hematological remission.
在急性淋巴细胞白血病患儿的淋巴母细胞以及14种永久性生长的淋巴母细胞样细胞系上证实了B细胞同种抗原。选用的4名经产妇的混合血清和一种兔抗血清用作特异性抗血清。与用人抗血清相比,用异源抗体能更有效地检测到抗原。原代淋巴母细胞的特征是具有B细胞同种抗原,且同一细胞上缺乏膜免疫球蛋白和Fc受体。通过免疫特征分析比通过细胞学评估能更好地监测缓解质量,即复发的早期诊断。对8例初发白血病患者、13例部分缓解患者和30例血液学完全缓解患者的骨髓进行了检查。在初始抗白血病化疗4周后,在骨髓中观察到免疫检查和细胞学检查之间存在明显差异。那时,尽管细胞学评估显示已经完全血液学缓解,但在免疫评估中仍可计数到数量增加的母细胞样细胞。